Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)
ALC-DRD2-APO
2 other identifiers
interventional
50
1 country
1
Brief Summary
OH dependence is associated with DA receptor changes. Both, the apomorphine test and the D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a marker of relapse in detoxified OH dependents patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Jan 2007
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
February 16, 2007
CompletedFirst Posted
Study publicly available on registry
February 19, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedApril 29, 2009
April 1, 2009
2.9 years
February 16, 2007
April 28, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To detertmine the agreement rate of the dopaminergic sensibility assessed by two different techiniques: the apomorphine test and and IBZM SPECT.
3 months
Interventions
Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
Eligibility Criteria
You may qualify if:
- alcohol dependence
- alcohol dependence length at least 8 years.
- male
- age 25 - 60 years
You may not qualify if:
- other drug dependence (except nicotine dependence)
- another major axis I psychiatric diagnosis
- comorbid neurological disorder
- comorbid cardiovascular disorder
- comorbid metabolic disorder
- brain injury
- apomorphine allergy
- iode allergy
- diazepam allergy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Psychiatry Service, Hospital Universitari Vall d'Hebron
Barcelona, Catalonia, 08036, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Miquel Casas, Prof
Psychiatry Service, Hospital Universitari Vall d'Hebron
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 16, 2007
First Posted
February 19, 2007
Study Start
January 1, 2007
Primary Completion
December 1, 2009
Study Completion
June 1, 2010
Last Updated
April 29, 2009
Record last verified: 2009-04